quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 23, 2026

Salesforce: Boring on the Surface, Dangerous to Ignore

View original at finance.yahoo.com
Salesforce: Boring on the Surface, Dangerous to Ignore This article first appeared on GuruFocus. Looking at the current state of the tech market, I see a fascinating disconnect between reality and sentiment…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • More than half of the new bookings for AI products (Agentforce and Data Cloud) are coming from existing customers

    80% confidence
  • Salesforce is successfully selling the AI agents themselves, opposite to fears that AI will replace human workers and shrink revenue

    80% confidence
  • Management noted that for the first time in years, the deal size for new business is growing faster than the deal size for existing business renewals

    80% confidence
  • Management signaled they are going to accelerate share buybacks in the second half of the fiscal year

    80% confidence
  • The narrative has been dominated by fears that artificial intelligence will disrupt Salesforce's business model

    80% confidence
  • If the stock simply re-rated to its average historical P/E multiple of around 22x, the price would jump to over $280

    80% confidence
  • Rating Salesforce as 'Strong Buy' with expected fair value of roughly $314 per share

    80% confidence
  • The market is treating Salesforce like a boring legacy company that has seen its best days

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Salesforce: Boring on the Surface, Dangerous to Ignore — Source | Via News | pt.VIA.NEWS